$-0.06 EPS Expected for Alimera Sciences, Inc. (ALIM)

October 14, 2018 - By Hazel Jackson

Alimera Sciences, Inc. (NASDAQ:ALIM) LogoInvestors sentiment decreased to 0.93 in Q2 2018. Its down 0.57, from 1.5 in 2018Q1. It turned negative, as 7 investors sold Alimera Sciences, Inc. shares while 8 reduced holdings. 8 funds opened positions while 6 raised stakes. 29.19 million shares or 2.32% more from 28.53 million shares in 2018Q1 were reported.
Vanguard Gru Inc invested in 0% or 2.08 million shares. Boothbay Fund Mgmt Lc stated it has 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Geode Mngmt Ltd Llc accumulated 144,795 shares. Cambridge Invest Rech holds 0% or 23,800 shares in its portfolio. Barclays Public Limited Liability Corp reported 0% stake. Retail Bank Of Montreal Can has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Bridgeway Mgmt holds 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM) for 489,825 shares. Weiss Multi invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Venbio Select Advisor Ltd holds 0.24% or 6.24M shares. Armistice Limited Co reported 0.44% in Alimera Sciences, Inc. (NASDAQ:ALIM). Signaturefd Limited reported 0% stake. Blackrock has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Knott David M stated it has 0.1% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Tower Research Ltd Llc (Trc) owns 1,439 shares or 0% of their US portfolio. Strs Ohio stated it has 0% in Alimera Sciences, Inc. (NASDAQ:ALIM).

Since May 7, 2018, it had 1 insider buy, and 0 selling transactions for $10,500 activity.

Analysts expect Alimera Sciences, Inc. (NASDAQ:ALIM) to report $-0.06 EPS on November, 7.They anticipate $0.02 EPS change or 50.00 % from last quarter’s $-0.04 EPS. After having $-0.06 EPS previously, Alimera Sciences, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.50% or $0.0143 during the last trading session, reaching $0.97. About 36,920 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 21.99% since October 14, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Alimera Sciences, Inc. (NASDAQ:ALIM) Ratings Coverage

Among 2 analysts covering Alimera (NASDAQ:ALIM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alimera had 3 analyst reports since May 8, 2018 according to SRatingsIntel. H.C. Wainwright maintained Alimera Sciences, Inc. (NASDAQ:ALIM) rating on Tuesday, May 8. H.C. Wainwright has “Buy” rating and $2.5000 target. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, June 12.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $67.94 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News